Australia · Delayed Price · Currency is AUD Integral Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 55.6% to AUD 393.5 million, with EBITDA margin up 230 bps to 20.6% and strong synergy realization from the Capitol merger. Ongoing investments in AI, teleradiology, and new sites support further growth, while integration costs are trending down.
Fiscal Year 2025
-
The meeting highlighted strong revenue and margin growth, successful Capital Health merger integration, and robust sustainability and governance initiatives. Shareholders approved all resolutions, with a focus on radiologist recruitment, AI adoption, and continued industry expansion.
-
Revenue grew 33.7% to $628M, driven by the Capital Health merger and organic growth, with EBITDA margin up to 20.1%. Annualized merger synergies are now $14M, and FY 2026 guidance points to further margin and revenue expansion, supported by MRI deregulation and new screening programs.
-
Revenue and EBITDA grew solidly, with strong NPAT and free capital flow, though margins were pressured by regional labor costs and contract caps. Merger synergies, MRI deregulation, and the lung cancer screening program are expected to drive future growth and margin improvement.
Fiscal Year 2024
-
The AGM covered a year of solid operational improvement, with revenue and EBITDA growth despite a statutory loss from a New Zealand impairment. Strategic focus included a major merger, board renewal, and ESG progress. All resolutions were presented and voting proceeded smoothly.
-
Revenue grew 6.6% to AUD 469.7M and operating EBITDA rose 7.4% to AUD 91.5M, with improved margins and strong free cash flow. A statutory loss was recorded due to a New Zealand impairment, but the outlook is positive with a major merger and regulatory changes expected to drive growth.
-
A transformative merger will create a leading diagnostic imaging provider in ANZ, combining complementary networks and unlocking at least AUD 10 million in annual cost synergies. The deal is expected to deliver double-digit EPS accretion, with minimal regulatory hurdles anticipated.
-
A merger is proposed to create a leading diagnostic imaging group in Australia and New Zealand, offering significant scale, clinical depth, and at least AUD 10 million in annual cost synergies. The deal is structured as a share exchange, with integration and regulatory approvals expected over several months.